Quick Win by the Algorithm: Nektar Therapeutics (NASDAQ: NKTR) Treats Investors With Stock Up 383.54% In 1 Year

Quick Algorithm

“This past year was truly transformational for Nektar as we achieved a number of successes with Nektar medicines across our three key therapeutic areas of immuno-oncology, immunology and pain”

– Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics

(Image Source: Nektar)

Over the past year Nektar Therapeutic’s stock price steadily grew from $21.60 to $104.51 per share, outperforming the market by more than 365%. So what is the driver behind that growth  and what happened during 2017 financial year? The reason lies in the company’s results

Read More